These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 28861727)

  • 1. Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?
    Hayton C; Chaudhuri N
    Drugs Aging; 2017 Sep; 34(9):647-653. PubMed ID: 28861727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
    Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
    Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
    Flaherty KR; Fell CD; Huggins JT; Nunes H; Sussman R; Valenzuela C; Petzinger U; Stauffer JL; Gilberg F; Bengus M; Wijsenbeek M
    Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety of new drug treatments for idiopathic pulmonary fibrosis.
    Fletcher S; Jones MG; Spinks K; Sgalla G; Marshall BG; Limbrey R; Richeldi L
    Expert Opin Drug Saf; 2016 Nov; 15(11):1483-1489. PubMed ID: 27532218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series.
    Delanote I; Wuyts WA; Yserbyt J; Verbeken EK; Verleden GM; Vos R
    BMC Pulm Med; 2016 Nov; 16(1):156. PubMed ID: 27863518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
    Kou M; Jiao Y; Li Z; Wei B; Li Y; Cai Y; Wei W
    Eur J Clin Pharmacol; 2024 Oct; 80(10):1445-1460. PubMed ID: 38963453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
    Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
    Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis.
    Sathiyamoorthy G; Sehgal S; Ashton RW
    South Med J; 2017 Jun; 110(6):393-398. PubMed ID: 28575896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.
    Maher TM; Strek ME
    Respir Res; 2019 Sep; 20(1):205. PubMed ID: 31492155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
    Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
    Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
    BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.
    Galli JA; Pandya A; Vega-Olivo M; Dass C; Zhao H; Criner GJ
    Respirology; 2017 Aug; 22(6):1171-1178. PubMed ID: 28317233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.
    Fleetwood K; McCool R; Glanville J; Edwards SC; Gsteiger S; Daigl M; Fisher M
    J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S5-S16. PubMed ID: 28287346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pirfenidone treatment of idiopathic pulmonary fibrosis.
    Azuma A
    Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.
    Collins BF; Raghu G
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31578210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and safety of treatment switch from Pirfenidone to Nintedanib in patients with idiopathic pulmonary fibrosis: a real-world observational study.
    Ntolios P; Archontogeorgis K; Anevlavis S; Bonelis K; Paxinou N; Voulgaris A; Froudarakis M; Steiropoulos P
    Eur Rev Med Pharmacol Sci; 2021 Oct; 25(20):6326-6332. PubMed ID: 34730213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    Xaubet A; Serrano-Mollar A; Ancochea J
    Expert Opin Pharmacother; 2014 Feb; 15(2):275-81. PubMed ID: 24308635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
    Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
    Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis.
    King CS; Nathan SD
    Curr Opin Pulm Med; 2015 Sep; 21(5):479-89. PubMed ID: 26164298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.